Treating iron deficiency in patients with heart failure: what, why, when, how, where and who - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39160066/
For patients with heart failure and reduced or mildly reduced left ventricular ejection fraction, iron deficiency is common and associated with more severe symptoms, worse quality of life and an...
Iron deficiency in heart failure worsens outcomes but improves with intravenous iron therapy. Current diagnostic criteria are flawed; targeting transferrin saturation <20% may enhance treatment response and patient care.
Diagnosis and management of cancer therapy-related myocarditis in a young female: A case report and review of literature - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38858610/
In this case, based on negative tests and the absence of viral signs and symptoms, Cancer therapy-related myocarditis is highly suspected as the cause of myocarditis. This case underscores the...
A 19-year-old with ES/PNET treated with VAC/IE developed chemotherapy-related myocarditis. Diagnosed via CMR, she responded significantly to IVIG, improving LVEF, highlighting its potential for treating reversible myocarditis.
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38265835/
ClinicalTrials.gov Identifier: NCT03619213.
Dapagliflozin reduces cardiovascular death, particularly sudden death, in HFimpEF patients, supporting its use with guideline-directed therapies to lower mortality in this understudied heart failure subgroup.
Inflammation in heart failure: pathophysiology and therapeutic strategies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38546848/
A role for inflammation in the development and progression of heart failure (HF) has been proposed for decades. Multiple studies have demonstrated the potential involvement of several groups of cytokines...
This review explores the role of inflammation in heart failure (HF) across ejection fraction phenotypes, focusing on biomarkers, immune pathways, and the potential of targeting inflammation in existing and future HF therapies.
Treating heart failure by targeting the vagus nerve - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39117958/
Increased sympathetic and reduced parasympathetic nerve activity is associated with disease progression and poor outcomes in patients with chronic heart failure. The demonstration that markers of autonomic imbalance and vagal...
In chronic heart failure, increased sympathetic and reduced parasympathetic activity worsen outcomes. This review explores the role of parasympathetic dysfunction, assessment methods, and the potential of parasympathetic stimulation therapies.